197 related articles for article (PubMed ID: 19519294)
1. The intermediate enzymes of isoprenoid metabolism as anticancer targets.
Wiemer AJ; Hohl RJ; Wiemer DF
Anticancer Agents Med Chem; 2009 Jun; 9(5):526-42. PubMed ID: 19519294
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS.
Henneman L; van Cruchten AG; Kulik W; Waterham HR
Biochim Biophys Acta; 2011 Apr; 1811(4):227-33. PubMed ID: 21237288
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma.
Haney SL; Holstein SA
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613550
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes.
Dudakovic A; Wiemer AJ; Lamb KM; Vonnahme LA; Dietz SE; Hohl RJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):1028-36. PubMed ID: 18083912
[TBL] [Abstract][Full Text] [Related]
5. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
Thurnher M; Nussbaumer O; Gruenbacher G
Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
[TBL] [Abstract][Full Text] [Related]
6. In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.
Haney SL; Varney ML; Chhonker Y; Talmon G; Smith LM; Murry DJ; Holstein SA
Pharmacol Res; 2021 May; 167():105528. PubMed ID: 33667685
[TBL] [Abstract][Full Text] [Related]
7. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.
Haney SL; Wills VS; Wiemer DF; Holstein SA
Molecules; 2017 May; 22(6):. PubMed ID: 28555000
[TBL] [Abstract][Full Text] [Related]
9. Amides as bioisosteres of triazole-based geranylgeranyl diphosphate synthase inhibitors.
Goetz DB; Varney ML; Wiemer DF; Holstein SA
Bioorg Med Chem; 2020 Aug; 28(16):115604. PubMed ID: 32690260
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of a series of aromatic bisphosphonates.
Barney RJ; Wasko BM; Dudakovic A; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2010 Oct; 18(20):7212-20. PubMed ID: 20832326
[TBL] [Abstract][Full Text] [Related]
11. In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors.
Reilly JE; Zhou X; Tong H; Kuder CH; Wiemer DF; Hohl RJ
Biochem Pharmacol; 2015 Jul; 96(2):83-92. PubMed ID: 25952057
[TBL] [Abstract][Full Text] [Related]
12. α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Matthiesen RA; Varney ML; Xu PC; Rier AS; Wiemer DF; Holstein SA
Bioorg Med Chem; 2018 Jan; 26(2):376-385. PubMed ID: 29248353
[TBL] [Abstract][Full Text] [Related]
13. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside.
Oldfield E
Acc Chem Res; 2010 Sep; 43(9):1216-26. PubMed ID: 20560544
[TBL] [Abstract][Full Text] [Related]
14. Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase.
Zhou X; Ferree SD; Wills VS; Born EJ; Tong H; Wiemer DF; Holstein SA
Bioorg Med Chem; 2014 May; 22(9):2791-8. PubMed ID: 24726306
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.
Agabiti SS; Liang Y; Wiemer AJ
Mol Membr Biol; 2016 Mar; 33(1-2):1-11. PubMed ID: 27537059
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer therapy: targeting the mevalonate pathway.
Swanson KM; Hohl RJ
Curr Cancer Drug Targets; 2006 Feb; 6(1):15-37. PubMed ID: 16475974
[TBL] [Abstract][Full Text] [Related]
17. The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms.
Ahmadi Y; Ghorbanihaghjo A; Argani H
Chem Biol Interact; 2017 Aug; 273():273-285. PubMed ID: 28668359
[TBL] [Abstract][Full Text] [Related]
18. Impact of α-modifications on the activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Fairweather AER; Goetz DB; Schroeder CM; Bhuiyan NH; Varney ML; Wiemer DF; Holstein SA
Bioorg Med Chem; 2021 Aug; 44():116307. PubMed ID: 34298413
[TBL] [Abstract][Full Text] [Related]
19. Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase.
Wills VS; Metzger JI; Allen C; Varney ML; Wiemer DF; Holstein SA
Bioorg Med Chem; 2017 Apr; 25(8):2437-2444. PubMed ID: 28302510
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution.
Haney SL; Chhonker YS; Varney ML; Talmon G; Smith LM; Murry DJ; Holstein SA
J Pharmacol Exp Ther; 2019 Nov; 371(2):327-338. PubMed ID: 31420526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
